Taysha Gene Therapies Stock Forecast, Price & News

Taysha Gene Therapies (NASDAQ:TSHA) Frequently Asked Questions

Is Taysha Gene Therapies a buy right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Taysha Gene Therapies in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Taysha Gene Therapies stock.
View analyst ratings for Taysha Gene Therapies or view top-rated stocks.

Are investors shorting Taysha Gene Therapies?

Taysha Gene Therapies saw a increase in short interest in December. As of December 31st, there was short interest totaling 3,010,000 shares, an increase of 18.0% from the December 15th total of 2,550,000 shares. Based on an average trading volume of 178,800 shares, the short-interest ratio is currently 16.8 days. Approximately 14.3% of the shares of the stock are sold short.
View Taysha Gene Therapies' Short Interest.

When is Taysha Gene Therapies' next earnings date?

Taysha Gene Therapies is scheduled to release its next quarterly earnings announcement on Wednesday, March 2nd 2022.
View our earnings forecast for Taysha Gene Therapies.

How were Taysha Gene Therapies' earnings last quarter?

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) released its earnings results on Wednesday, November, 10th. The company reported ($1.35) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.02) by $0.33. During the same period in the previous year, the company posted ($1.28) earnings per share.
View Taysha Gene Therapies' earnings history.

What price target have analysts set for TSHA?

10 equities research analysts have issued twelve-month target prices for Taysha Gene Therapies' stock. Their forecasts range from $28.00 to $60.00. On average, they anticipate Taysha Gene Therapies' stock price to reach $43.70 in the next twelve months. This suggests a possible upside of 508.6% from the stock's current price.
View analysts' price targets for Taysha Gene Therapies or view top-rated stocks among Wall Street analysts.

Who are Taysha Gene Therapies' key executives?

Taysha Gene Therapies' management team includes the following people:

• Mr. R. A. Session II, Founder, Pres, CEO & Director (Age 42, Pay $634.63k) (LinkedIn Profile)
• Mr. Kamran Alam CPA, M.B.A., Chief Financial Officer (Age 43, Pay $756.38k) (LinkedIn Profile)
• Dr. Suyash Prasad FFPM, M.Sc., MBBS, M.D., M.B.B.S., F.F.P.M, Chief Medical Officer and Head of R&D (Age 51, Pay $501.78k)
• Mr. Fred Porter Ph.D., Chief Technical Officer
• Mr. Jim Rouse, Chief Information Officer
• Dr. Kimberly Lee D.O., Sr. VP of Corp. Communications & Investor Relations
• Mr. Timothy J. Douros J.D., Chief Legal Officer & Corp. Sec.
• Ms. Tracy M. Porter, Chief People Officer
• Ms. Emily McGinnis M.P.H., Chief Patient Officer & Head of Gov. Affairs
• Ms. Mishima Gerhart, Chief Regulatory Officer & Head of Quality

Who are some of Taysha Gene Therapies' key competitors?

Some companies that are related to Taysha Gene Therapies include REGENXBIO (RGNX), C4 Therapeutics (CCCC), Vaxcyte (PCVX), Inhibrx (INBX), Immunocore (IMCR), Coherus BioSciences (CHRS), Sorrento Therapeutics (SRNE), Molecular Partners (MOLN), Replimune Group (REPL), Sangamo Therapeutics (SGMO), Immunovant (IMVT), Adagio Therapeutics (ADGI), SOPHiA Genetics (SOPH), Century Therapeutics (IPSC) and Agenus (AGEN).
View all of TSHA's competitors.

When did Taysha Gene Therapies IPO?

(TSHA) raised $125 million in an IPO on Thursday, September 24th 2020. The company issued 6,600,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Chardan was co-manager.

What is Taysha Gene Therapies' stock symbol?

Taysha Gene Therapies trades on the NASDAQ under the ticker symbol "TSHA."

How do I buy shares of Taysha Gene Therapies?

Shares of TSHA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Taysha Gene Therapies' stock price today?

One share of TSHA stock can currently be purchased for approximately $7.18.

How much money does Taysha Gene Therapies make?

Taysha Gene Therapies has a market capitalization of $276.24 million.

How many employees does Taysha Gene Therapies have?

Taysha Gene Therapies employs 38 workers across the globe.

What is Taysha Gene Therapies' official website?

The official website for Taysha Gene Therapies is www.tayshagtx.com.

Where are Taysha Gene Therapies' headquarters?

Taysha Gene Therapies is headquartered at 2280 Inwood Road, DALLAS TX, 75235.

How can I contact Taysha Gene Therapies?

Taysha Gene Therapies' mailing address is 2280 Inwood Road, DALLAS TX, 75235. The company can be reached via phone at 214-612-0000 or via email at [email protected].